EAU 2008 - Vitespen Vaccine Demonstrates Possible Benefit for a Specific Subgroup of Renal Cancer Patients
MILAN, ITALY (UroToday.com) - An autologous heat shock peptide vaccine called Vitespen demonstrated a possible benefit for a specific subgroup of patients in a randomized open phase-III trial.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2010 UroToday ® All Rights Reserved |
